Usage and dosage of capicitinib tablets and clinical medication regimens for different patients

Capivasertib (also known as caposertib) is an oral small molecule AKT inhibitor, mainly used to treat patients with breast cancer and some solid tumors associated with activation of the PI3K/AKT/mTOR pathway. It inhibits tumor proliferation by inhibiting AKT kinase activity and blocking growth and survival signals of tumor cells. The drug can be used alone or in combination with endocrine therapy drugs, and the medication regimen can be adjusted according to the patient's condition, genetic background and tolerance.

Standard adult dosage is usually 400 mg, taken orally twice daily for four consecutive days followed by three days off, with one course of treatment lasting one week, and every 28 days as a complete course of treatment. This program is suitable for adult patients with normal basic body weight and normal liver and kidney function. The drug should be taken on an empty stomach or with a small amount of food to ensure drug absorption. At the same time, avoid taking it with strong CYP3A4 inhibitors or inducers to avoid affecting drug concentration and efficacy.

For elderly patients or patients with mild to moderate liver and renal impairment, the dosage can be appropriately reduced or the dosing frequency adjusted under the guidance of a doctor to reduce the risk of adverse reactions. Common adverse reactions include hyperglycemia, diarrhea, rash, fatigue and nausea. Blood sugar, liver function and kidney function need to be monitored regularly, and symptomatic treatment should be taken according to the symptoms. Patients receiving combined chemotherapy or endocrine therapy also need to pay attention to cumulative toxicity and tolerance between drugs.
In clinical practice, the dosage regimen of capiseti tablets will be adjusted according to individual circumstances. For example, for patients with gene mutation breast cancer, it can be used in combination with aromatase inhibitors or selective estrogen receptor modulators to improve the efficacy; for patients with poor tolerance or combined with underlying diseases, they can start with a low dose and gradually adjust to a standard dose. At the same time, efficacy indicators and adverse reactions should be followed up regularly to ensure treatment safety and optimize clinical effects, and provide personalized treatment plans for different types of patients.
Reference: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/capivasertib